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ABSTRACT
There are mixed reports on the role that IGFBP-2 plays in cancer progression, 
with some indicating a tumour suppressive role and others showing that IGFBP-2 
may act as an oncogene. These apparent contradictions may be context and tissue 
specific. In this study we determined the role that IGFBP-2 played on the phenotype 
and chemosensitivity of a selection of bladder cancer cell lines and investigated 
how the abundance of IGFBP-2 was regulated. We found that IGFBP-2 was more 
abundant in the epithelial bladder cancer cells, RT4 and UMUC3 and absent in the more 
mesenchymal T24 and TCCSUP cells. Silencing IGFBP-2 using siRNA in epithelial RT4 
cells promoted cell proliferation, invasion, colony formation, resulted in a reduction 
in epithelial (E-cadherin) and an increase in mesenchymal (N-cadherin) markers and 
increased sensitivity to cisplatin-induced cell death. Conversely, we observed the 
opposite effects when adding exogenous IGFBP-2 to the mesenchymal T24 cells. We 
determined that IGFBP-2 was epigenetically silenced via DNA methylation as the cells 
adopted a mesenchymal phenotype. Collectively these data suggest that IGFBP-2 acts 
as a tumour suppressor and marker of chemosensitivity in epithelial bladder cancer 
cells and that IGFBP-2 is epigenetically silenced by methylation to promote bladder 
cancer progression.
INTRODUCTION
Epithelial-to-mesenchymal transition (EMT) describes 
the process by which cells change from an adherent 
epithelial into a highly motile mesenchymal-like cell. 
EMT is characterised by alterations in the abundance 
of epithelial cell surface markers, such as a reduction 
in E-cadherin [1] and the acquisition of mesench-ymal 
proteins, such as N-cadherin [2]. The loss of epithelial 
features and a gain of mesenchymal characteristics 
is associated with increases in cell proliferation, 
migration and invasion, and an increase in colony 
formation [3–5].
IGFBP-2 acts in both IGF-dependent and 
-independent ways. In the presence of IGFs, IGFBP-2 
reduces the effects of IGFs by sequestering free bioactive 
IGFs into inactive IGF:IGFBP-2 complexes [6], and 
the intrinsic IGF-independent effects, that have been 
demonstrated in many cancers occurs by binding, via 
their RGD sequence, to integrin receptors, similar to 
that reported in prostate [7]. The IGFs are widespread 
regulators of most cell functions; their interactions with 
IGFBPs can reduce the clearance of IGFs, sequester 
IGFs in the extracellular matrix or on cell surfaces, via 
interactions with proteoglycans, and hence enhance 
targeting of the IGFs to specific sites of action and 
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also constrain receptor binding by competition. The 
different effects of IGFBPs depend on interactions with 
extracellular matrix, cell surfaces and extracellular 
proteases; all of which can vary in a tissue specific manner 
and therefore confer specificity, depending on context, to 
the multiple potential IGF actions [8].
There are mixed reports on the role of insulin-
like growth factor binding protein-2 (IGFBP-2) in 
cancer progression. Some studies report that it acts 
as an oncogene as it is commonly expressed in high 
grade tumours and promotes cancer development and 
progression in a number of cancers, including those of the 
breast [9–11], prostate [7, 12] and brain [13, 14]. However, 
others report that aggressive cancers have little or no 
expression of IGFBP-2 compared with more differentiated 
forms of the tumours. For example, increased levels of 
IGFBP-2 are found in rapidly growing non-invasive brain 
tumours, whereas low/undetectable levels are observed in 
malignant invasive brain tumours [15].
There are limited reports on the role of IGFBP-2 in 
bladder cancer progression. In 2005, it was reported that 
over-expressing IGFBP-2 in KoTCC-1 cells (established 
from the ascites of a 23-year-old woman with peritonitis 
carcinomatosa) that possess little IGFBP-2, caused 
the cells to become more proliferative and motile [16]. 
The same group also determined that IGFBP-2 mRNA 
expression levels and the relative expression ratio of 
IGFBP-2 to IGFBP-3 mRNAs in 97 bladder cancer 
specimens significantly correlated with pathological stage, 
lymph node metastasis and vascular invasion [16]. These 
data suggest that IGFBP-2 may play a role in promoting 
progression of bladder cancer.
The apparent contradictions in the role of IGFBP-2 
in relation to its expression may be explained by the 
different ways in which IGFBP-2 can be regulated, 
that will be specific to the context of a tissue-type. 
For example, the levels and function of IGFBP-2 can 
be regulated by promoter methylation, hormones and 
proteases (see review [17]).
In this study we determined the role that IGFBP-2 
played on proliferation, invasion, EMT, colony formation 
and chemosensitivity in a selection of bladder cancer cell 
lines and investigated how the abundance of IGFBP-2 was 
regulated.
RESULTS
We initially assessed the levels of IGFBP-2 in 
relation to the epithelial or mesenchymal characteristics 
of each of the cell lines. RT4 cells are the most epithelial-
like with high levels of E-cadherin and no N-cadherin; 
these cells exhibited the highest levels of IGFBP-2. T24 
cells were the most mesenchymal-like demonstrating 
the highest levels of N-cadherin with no E-cadherin: we 
observed that this cell line also had undetectable levels of 
IGFBP-2. Similarly, TCCSUP, another mesenchymal cell 
line, has low levels of N-cadherin, no E-cadherin and low 
levels of IGFBP-2. UMUC3 is classified as epithelial-like 
despite having negligible levels of E-cadherin, however, it 
did produce relatively small amounts of IGFBP-2 and had 
no N-cadherin (see Supplementary Figure 1A).
Effect of silencing IGFBP-2 in epithelial RT4 
cells on the growth, invasion, colony formation 
and abundance of EMT markers
With IGFBP-2 silenced using siRNA an increase in 
both total cell number (by 27.2% (p<0.001)) and live cell 
number (by 21.6% (p<0.01)) was observed (Figure 1A). 
There were no significant changes in the level of cell death 
between the two groups (Figure 1B). Effective silencing of 
IGFBP-2 is indicated in Figure 1A insert. A 68% increase 
(p<0.05) in cell invasion (Figure 1C&D) was detected. 
Effective silencing of IGFBP-2 is indicated in Figure 1C 
insert. The cells with IGFBP-2 silenced formed more and 
larger colonies: a 15% increase in colony forming efficiency 
(CFE) (p<0.01) (Figure 1E&F) with a 1.38 fold increase in 
the average size of each colony (p<0.01) (Figure 1E&G). 
Effective silencing of IGFBP-2 is indicated in Figure 1E 
insert. These phenotypic changes in response to silencing 
IGFBP-2 (Figure 1H insert) were associated with a marked 
reduction in the epithelial marker E-cadherin (p<0.05) but 
no apparent induction of N-cadherin (Figure 1H).
Effect of adding exogenous IGFBP-2 to 
mesenchymal T24 and TCCSUP cells on 
the growth, invasion, colony formation and 
abundance of EMT markers
T24 and TCCSUP cells were treated with an effective 
anti-proliferative dose of IGFBP-2 (600 ng/ml) determined 
from dose response curves (Supplementary Figure 1B). 
Exogenous addition of IGFBP-2 to T24 and TCCSUP 
cells showed a 25.8% and 20.2% decrease in total cell 
number respectively (p<0.001 for each) and a 25.9% and 
21.1 % reduction in live cell number (p<0.001 & p<0.005) 
respectively (Figure 2A&B) with no change in cell death 
(Figure 2C&D). Exogenous IGFBP-2 also induced a 55% 
and 41% decrease in cell invasion in T24 (Figure 2E) and 
TCCSUP cells (Figure 2F) respectively (p<0.001 for each). 
A reduction in colony formation of 78.8% (p<0.001) (Figure 
2G&H) and of 87.6% (p<0.001) (Figure 2J&K) was found 
in IGFBP-2-treated T24 and TCCSUP cells, respectively. 
Similarly, the fold decrease in average size of each colony 
were 0.60 (p<0.001) (Figure 2G&I) and 0.57 (p<0.01) 
(Figure 2H&L) respectively. The phenotypic changes in 
response to the exogenous addition of IGFBP-2 in T24 
cells were accompanied by a 59% (p<0.05) reduction in the 
abundance of N-cadherin with no detectable induction of 
E-cadherin (Figure 2M). Effects of IGFBP-2 on N-cadherin 
were not assessed in the TCCSUP cell line as levels of 
N-cadherin are relatively low already.
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Figure 1: Shows the effect of IGFBP-2 silencing in RT4 cells on (A) total cell number (B) cell death (C & D) invasion (image 
shows invaded cells with the nuclei stained with DAPI (in blue); X 10 magification) and graph indicates the mean change 
in number of invaded cells (E) colony formation; images of cells on day 1 and of colonies on day 21; x 10 magnification. 
(F&G) graphs represent the change in colony count and fold change of the average colony size respectively. (H) EMT 
markers, E- and N-cadherin and the graph shows the mean optical density change in E-cadherin. Inserts in A, C, E & H show 
a Western blot indicating effective IGFBP-2 silencing. Graphs show the mean and SEM of data from 3 separate experiments 
each performed in triplicate. Data were analysed with SPSS 12.0.1 for Windows using one-way ANOVA followed by least 
significant difference (LSD) post-hoc test. A statistically significant difference was present at p<0.05. NS= non-silencing 
control, KD= knockdown with siRNA.
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Figure 2: Shows the effects of adding exogenous IGFBP-2 (600ng/ml) to T24 and TCCSUP cells on (A & B) total cell number 
respectively, (C & D) cell death respectively (E & F) invasion (images show invaded cells with the nuclei stained with DAPI (in 
blue); X 10 magification and graph indicates the mean change in number of invaded cells (G, H & I) colony formation for T24 
cells; images of cells on day 1 and of colonies on day 28; x 10 magnification. Graphs represent the change in colony count and 
fold change of the average colony size. Graphs show the mean and SEM of data from 3 separate experiments each performed in 
triplicate. Data were analysed with SPSS 12.0.1 for Windows using one-way ANOVA followed by least significant difference 
(LSD) post-hoc test. A statistically significant difference was present at p<0.05. CT=control. (Continued).
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To determine if the phenotypic effects of 
IGFBP-2 are independent of IGF-I
Figure 3A shows that with RT4 cells pre-treatment 
with NBI-31772 alone led to a significant increase in 
cell growth (21.7% p<0.05), suggesting that IGFs had 
been released from IGFBPs, predominantly IGFBP-2 
as this is the main one secreted by these cells, and 
were able to increase cell growth. This indicates that 
IGFBPs, predominantly IGFBP-2, acts at least partly by 
sequestering IGFs since when IGFs are displaced from the 
IGFBPs this stimulates cell growth and silencing IGFBP-2, 
when it can no longer sequester IGFs also results in cell 
growth. Silencing IGFBP-2, as we observed previously, 
caused an increase in cell growth (by 40.9%) of RT4 
cells. In the presence of NBI-31772, silencing IGFBP-2 
still induced a comparable increase in cell growth which 
was additive to the effects of NBI-31772 alone on cell 
growth (66.3%, p<0.001). In the presence of NBI-31772, 
when any interaction of IGFBP-2 with IGFs is prevented, 
Figure 2 (Continued): (J-L) show the effects of adding exogenous IGFBP-2 (600 ng/ml) to TCCSUP cells on colony 
formation; images of cells on day 1 and of colonies on day 28; x 10 magnification. Graphs represent the change in 
colony count and fold change of the average colony size and (M) EMT markers, E- and N-cadherin and the graph 
shows the mean optical density change in N-cadherin. Graphs show the mean and SEM of data from 3 separate 
experiments each performed in triplicate. Data were analysed with SPSS 12.0.1 for Windows using one-way ANOVA 
followed by least significant difference (LSD) post-hoc test. A statistically significant difference was present at 
p<0.05. CT=control.
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the observation that silencing IGFBP-2 still results in 
cell growth indicates that the presence of IGFBP-2 can 
inhibit cell growth independent of any interaction with 
IGFs. In combination these results suggest that the effects 
of IGFBP-2 on these cells are both IGF-dependent and 
-independent. There were no effects on the levels of cell 
death (Figure 3B; effective silencing of IGFBP-2 shown 
in Figure 3A insert). We confirmed that exogenously 
added IGF-I was able to dose-dependently increase cell 
proliferation in the RT4 cells (Supplementary Figure 1D).
With RT4 cells, silencing IGFBP-2 alone increased 
cell invasion (by 33.1%) and in the presence of NBI-31772, 
silencing IGFBP-2 still induced a comparable increase in 
invasion which was additive to the effects of NBI-31772 
alone on cell invasion growth (56.9% <0.01), suggesting 
again both IGF-dependent and -independent effects of 
IGFBP-2 on invasion in RT4 cells (Figure 3C-effective 
silencing of IGFBP-2 shown in insert). We confirmed that 
exogenously added IGF-I was able to increase cell invasion 
in the RT4 cells (Supplementary Figure 1E&F).
Figure 3D shows that with T24 cells, exogenously 
added IGF-I induced a significant increase in total cell 
number (28.6%, p<0.001) while NBI-31772 did not, 
suggesting that no appreciable IGF was released from any 
IGFBPs present. Exogenous IGFBP-2 led to a decrease 
in cell growth (35.3%, p<0.001), and this effect was 
negated in the presence of NBI-31772, suggesting that 
exogenously added IGFBP-2 reduces cell growth through 
sequestering endogenous IGFs and can no longer do this in 
the presence of NBI-31772: this implies an IGF-dependent 
action of the exogenously added IGFBP-2 with these 
cells. There were no effects on the levels of cell death 
(Figure 3E).
With T24 cells, IGF-I induced a significant increase 
in cell invasion (45.5%, p<0.001) while NBI-31772 did 
not. Exogenous IGFBP-2 treatment led to a decrease in 
cell invasion (35%, p<0.001), and this was unaffected by 
the presence of NBI-31772 suggesting that the effects of 
IGFBP-2 on cell invasion were not blocked by NBI-31772 
and were therefore independent of IGFs (Figure 3F).
Assessment of epigenetic modification of 
IGFBP-2 in bladder cancer cells
To investigate whether the loss of IGFBP-2 in 
mesenchymal-like bladder cancer cells potentially 
resulted from epigenetic regulation, we initially treated the 
mesenchymal T24 and TCCSUP cells with a demethylating 
agent, AZA. We observed a clear increase in the abundance 
of IGFBP-2 following AZA-exposure in the T24 cells 
(Figure 4A&B) and this was less marked in the TCCSUP 
cells. Having shown that IGFBP-2 was re-expressed in 
T24 and TCCSUP cells following AZA treatment, COBRA 
was then performed with these two cell lines to assess 
any alterations in gene methylation status of the IGFBP-2 
promoter and to confirm whether the loss of IGFBP-2 in 
mesenchymal-like bladder cancer cell lines could be the 
result of an epigenetic change. With T24 cells, the promoter 
region of the IGFBP-2 gene was completely methylated 
in the control samples, and the treatment with AZA led to 
the demethylation of this gene with a significant increase 
in the percentage of unmethylated DNA bands from 0 (in 
control cells) to 39.9% (in AZA-treated cells) (p<0.001) 
(Figure 4E&F). With TCCSUP cells, very low levels of 
methylation were observed in the control cells. However, 
gene demethylation, but to a much smaller extent than 
observed in T24 cells, was detected in TCCSUP samples 
upon AZA treatment, with the percentage of unmethylated 
DNA bands increasing from 74.8% (in control cells) to 
88.6% (in AZA-treated cells) (p<0.01) (Figure 4G).
AZA mimics the phenotypic effects and the 
alterations in EMT markers observed in 
the presence of exogenous IGFBP-2 in T24 
mesenchymal-like bladder cancer cells
As a clear effect on the methylation of IGFBP-2 
following AZA treatment was observed in the T24 cells, 
we assessed if AZA mimicked the phenotypic effects of 
adding exogenous IGFBP-2. AZA decreased both total 
cell number (by 34.3%, p<0.001) and live cell number 
(by 36.4%, p<0.001) (Figure 5A). With T24 cells colony 
forming efficiency (CFE) decreased by 36.7% (p<0.01) 
and the average size of each colony showed a 0.6 fold 
decrease (p<0.001) relative to control cells (Figure 5B). 
With the treatment of AZA, the abundance of N-cadherin 
was reduced by 65% (p<0.05) with no observed changes 
in E-cadherin (Figure 5C).
The presence of IGFBP-2 in tumours may affect 
the response to chemotherapy
We observed that the epitehlial RT4 cells were more 
sensitive to cisplatin-induced cell death than the more 
mesenchymal T24 cells (Figure 6A). As T24 cells do not 
express IGFBP-2, we added exogenous IGFBP-2 in the 
presence or absence of cisplatin and found that although 
IGFBP-2 had no effect on cell death alone it markedly 
enhanced the sensitivity of the cells to cisplatin (p<0.01; 
Figure 6B). With RT4 cells, we silenced IGFBP-2 in the 
presence or absence of cisplatin and found that although 
silencing IGFBP-2 had no effect on cell death alone, it 
reduced the sensitivity of the cells to cisplatin (p<0.01; 
Figure 6C). These preliminary data in vitro data suggest 
that the presence of IGFBP-2 in tumours may play a role 
in determining chemosensitivity.
DISCUSSION
Our data suggest that IGFBP-2 acts to inhibit 
cell proliferation, invasion, colony formation and EMT 
in bladder cancer and its presence may play a role in 
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Figure 3: Shows the effects of manipulating IGFBP-2 in RT4 and T24 cells in the presence of NBI-31772 (1µM). (A, B & C)  
Show the effect of silencing IGFBP-2 in the presence or absence of NBI-31772 (NBI) in RT4 cells on total cell number, cell death and 
invasion respectively. (D, E & F) Show the effect of adding exogenous IGFBP-2 in the presence or absence of NBI-31772 in T24 cells on 
proliferation, cell death and invasion respectively. Inserts in A & C show a Western blot indicating effective IGFBP-2 silencing. Invasion 
images show invaded cells with the nuclei stained with DAPI (in blue); X 10 magification and the corresponding graph indicates the mean 
change in number of invaded cells. Graphs show the mean and SEM of data from 3 separate experiments each performed in triplicate. 
Data were analysed with SPSS 12.0.1 for Windows using one-way ANOVA followed by least significant difference (LSD) post-hoc test. A 
statistically significant difference was present at p<0.05.
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Figure 4: Effect of 5-AZA on the abundance and methylation status of the IGFBP-2 gene promoter. (A & B) show a 
Western blot of IGFBP-2 in the cell supernatant (neat, 10 and 20-fold concentrated) and a graph showing fold change in abundance after 
treatment with 5-AZA (10µM; 72 hrs) in T24 cells. (C & D) show the same as in A & B for TCCSUP cells. (E) shows a representative 
gel indicating methylated (M) and unmethylated (UM) bands representing IGFBP-2 following 5-AZA treatment of T24 cells and this 
is represented as % M and UM in the graph in (F). (G) shows a graphical representation of % M and UM bands representing IGFBP-2 
following 5-AZA treatment of TCCSUP cells. Gels and graphs are representative of experiments repeated at least three times. Graphs show 
the mean and SEM. Data were analysed with SPSS 12.0.1 for Windows using one-way ANOVA followed by least significant difference 
(LSD) post-hoc test. A statistically significant difference was present at p<0.05.
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determining chemosensitivity. Similar anti-proliferative 
effects of IGFBP-2 were reported in a human breast 
cancer cell line, Hs578T [18] and in human embryonic 
kidney fibroblasts [19]. Whereas opposite results have 
been reported in MCF7 and T47D breast cancer cells, 
hepatocellular carcinoma and glioma cells where IGFBP-2 
acted to promote cell growth [20, 21]. A reduction of 
IGFBP-2 was correlated with the promotion of epithelial 
invasion in the progression of cervical cancer [17], and 
loss of IGFBP-2 was also found at the invasive front 
of glioblastoma with high 8, line grade suggesting that 
IGFBP-2 is associated with a less aggressive phenotype 
[22]. However, in bladder cancer over-expression of 
IGFBP-2 enhanced the invasive potential of KoTCC 
Figure 5: Effect of 5-AZA on T24 cells with respect to (A) cell growth (B) colony formation; images of cells on day 1 and of 
colonies on day 28; x 10 magnification. Graphs represent the change in colony count and fold change of the average colony 
size respectively. (C) EMT markers, E- and N-cadherin and the graph shows the mean optical density change in N-cadherin. 
Graphs show the mean and SEM of data from 3 separate experiments each performed in triplicate. Data were analysed with 
SPSS 12.0.1 for Windows using one-way ANOVA followed by least significant difference (LSD) post-hoc test. A statistically 
significant difference was present at p<0.05.
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cells. Whilst these data contradict our results and suggest 
that IGFBP-2 plays a role in inhibiting malignant 
transformation in bladder cancer, the methodology used to 
assess the role of IGFBP-2 was very different. As KoTCC 
cells normally express negligible levels of IGFBP-2, the 
authors generated an IGFBP-2 KoTCC cell line that over-
expressed IGFBP-2. This may not be as physiologically 
relevant as adding exogenous IGFBP-2 at appropriate 
concentrations to IGFBP-2 null cells and may therefore 
not represent the context in vivo. Normally IGFBP-2 
is a secreted protein and many of its actions are due to 
interactions with IGFs and with cell-surface proteins/
receptors, although some is internalised and may act 
at critical sites within the cell. In contrast, forced over-
Figure 6: Effects of cisplatin on cell death in (A) RT4 and T24 cells and (B) in T24 cells following the addition of IGFBP-2 
(600ng/ml) and (C) in RT4 cells with IGFBP-2 silenced. Insert shows a blot to indicate effective knockdown of IGFBP-2. 
Graphs show the mean and SEM of data from 3 separate experiments each performed in triplicate. Data were analysed with 
SPSS 12.0.1 for Windows using one-way ANOVA followed by least significant difference (LSD) post-hoc test. A statistically 
significant difference was present at p<0.05.
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expression within the cell may not replicate these intricate 
interactions but may saturate binding sites within the 
cell. [16]. In contrast, with certain human leukaemias 
inhibition of IGFBP-2 resulted in a reduction in cell 
colony formation activity in a mouse model [23].
A number of changes occur in specific markers 
during EMT: for example, a reduction in the levels 
of E-cadherin and an increase in the abundance of 
N-cadherin. With RT4 cells, the levels of E-cadherin 
were significantly reduced when IGFBP-2 was efficiently 
silenced. Changes in RT4 cells indicated that silencing 
IGFBP-2 promoted a more EMT-like phenotype. While in 
mesenchymal-like T24 cells, adding exogenous IGFBP-2 
led to a significant reduction of N-cadherin expression 
suggesting inhibition of EMT. These data indicate that 
the presence of IGFBP-2 may suppress EMT in bladder 
cancer. As with cadherin switching, in relation to changing 
from an epithelial to a more mesenchymal cell type, our 
data appears to suggest that IGFBP-2 is more abundant in 
epithelial cells, where it is associated with maintaining a 
more differentiated phenotype. In contrast, mesenchymal 
bladder cancer cells appear to have negligible levels 
of IGFBP-2 that correlate with a more aggressive cell 
type. Again, different conclusions about the role of 
IGFBP-2 have been drawn in other types of cancers such 
as pancreatic ductal adenocarcinoma (PDAC), where 
IGFBP-2 promoted EMT: downregulation of N-cadherin 
and upregulation of E-cadherin followed knockdown of 
IGFBP-2 [24]. Its levels were altered depending on the 
aggressiveness of the cells, being abundant in the less 
advanced and absent in the most aggressive cells.
Dysregulation of IGFBPs as a result of epigenetic 
modifications has been identified in many tumours, such 
as aberrant DNA methylation of the promoter of IGFBP-2 
and IGFBP-3 genes in hepatomas and breast cancers 
respectively [25, 26]. We next investigated if altered 
methylation may be the mechanism by which IGFBP-2 
levels were being regulated in bladder cancer cells.
The mesenchymal-like IGFBP-2-negative cell lines, 
T24 and TCCSUP, were exposed to AZA, a commonly 
used demethylating agent: re-expression of IGFBP-2 was 
observed in both cell lines, and the increase in abundance 
of IGFBP-2 was more significant in T24 cells. In addition 
to enabling the re-expression of IGFBP-2, treatment 
with AZA also led to similar phenotypic changes that 
were observed on addition of exogenous IGFBP-2: with 
T24 cells, a reduction in abundance of the mesenchymal 
marker (N-cadherin), significant decreases in cell 
proliferation and colony formation.
COBRA confirmed that this increase in AZA-
induced IGFBP-2 was specifically due to changes in the 
methylation status of the promoter region of IGFBP-2 
gene in the T24 cells. In TCCSUP cells, as the increase in 
demethylation in response to AZA was small, we suggest 
that other epigenetic changes such as histone modification, 
which has been reported in prostate cancer [27], might 
also contribute to the loss of IGFBP-2.
Based on the reversible nature of epigenetic 
modifications, compared with genetic mutations, these 
findings suggest IGFBP-2 is switched off in advanced 
bladder cancer which eliminates the inhibitory effects 
of this protein on cell proliferation, invasion and colony 
formation in cancer development. In this study, we 
focussed on methylation but clearly there are other ways 
in which IGFBP-2 could be modified epigeneically; 
indeed we showed previously that the levels of IGFBP-2 
were enhanced via increased acetylation of histones H3 
and H4 associated with the IGFBP-2 gene promoter [27]. 
The results of the present study suggest that epigenetic 
modulation of the IGFBP-2 gene plays an important part in 
the loss of IGFBP-2 in progressive mesenchymal bladder 
cancers, which raises the possibility of epigenetically-
targeted cancer therapies for certain bladder cancer 
subtypes to restore a less aggressive phenotype [28, 29].
As it has been reported that IGFBP-2 can act in 
either an IGF-dependent or -independent or both manners, 
NBI-31772, as an inhibitor of IGF/IGFBP-2 interactions, 
was used to study how it works in bladder cancer. 
Stimulatory effects of pre-treatment with NBI-31772 alone 
on both cell growth and invasion of RT4 cells indicated 
that NBI-31772 freed endogenous IGFs from IGF:IGFBP 
complexes, mainly IGF:IGFBP-2, to act on the cells to 
promote growth and invasion alone. This suggested that 
endogenous IGFBP-2 was acting in an inhibitory manner 
in part through interactions with IGFs. Silencing IGFBP-2 
in RT4 cells also exerted promoting effects on both 
cell growth and invasion, and also stimulated the same 
percentage increase in the presence or absence of NBI-
31772, with the percentage change being additive to the 
effects of NBI-31772 lone, which suggested that IGFBP-2 
has the ability to act in both an IGF-dependent and 
-independent manner in epithelial-like bladder cancers. 
In IGFBP-2-null mesenchymal-like T24 cells, compared 
with the increase in cell growth and invasion following 
the addition of exogenous IGF-I, no notable difference 
was found when cells were treated with NBI-31772 alone, 
which indicated little endogenous IGFs were released from 
IGF:IGFBP complexes in these cells. Exogenously added 
recombinant IGFBP-2 led to a significant reduction both in 
cell growth and invasion of T24 cells. The inhibitory effect 
on growth was inhibited by the addition of NBI-31772. 
This suggested exogenous IGFBP-2 inhibited cell growth 
by sequestering endogenous IGFs and was no longer able 
to do this in the presence of NBI-31772, which implied an 
IGF-dependent action of the exogenously added IGFBP-2 
on T24 cell proliferation which has been reported in colon 
cancer [19]. However, the inhibitory effect of IGFBP-2 
on cell invasion was not affected by adding NBI-31772, 
thus indicating that IGFBP-2 acted in an IGF-independent 
manner to inhibit invasion of T24 cells.
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We observed that the mesenchymal T24 cells are 
more resistant to cisplatin than the RT4 epithelial-like 
cells. As T24 cells do not express IGFBP-2, we treated 
the cells with cisplatin and exogenous IGFBP-2 and 
found that chemosensitivity was improved. Conversely, 
silencing IGFBP-2 in the RT4 cells rendered the cells 
slightly more chemoresistant. A previous study in bladder 
cancer cells used the BIU87 cell line and established a 
cisplatin-resistant subline (BIU87-CisR) by continuous 
exposure of the cells to cisplatin. They found that the the 
cisplatin resistant subline produced more IGFBP-2 and 
concluded that IGFBP-2 contributed to chemoresistance 
[30]. Although seemingly different results the models used 
are quite different: perhaps upregulation of IGFBP-2 after 
generating a cisplatin resistant cell line is a compensatory 
response. In contrast to the sparce data on a possible 
role for IGFBP-2 in chemosensitivity of bladder cancer, 
there are convincing data indicating a role for ERCC2 
mutations. The abundance of these mutations is reported 
to be higher in primary compared with secondary muscle 
invasive bladder cancers (MIBC) and the reduced levels 
of these mutations in secondary MIBCs correlated with 
increased chemoresistance [31]. There is also little 
information about the relative abundance of IGFBP-2 in 
luminal versus basal bladder cancers. One study did assess 
mRNA levels of IGFBP-2 and IGFBP-3, and found that 
whilst a high IGFBP-2 to IGFBP-3 ratio did correlate 
with a lower recurrence -free survival compared to those 
with a normal ratio, there were no associations when 
assessing individual mRNA levels of these proteins [16]. 
These are interesting observations but a comprehensive 
study of IGFBP-2 in bladder tumours and its association 
with chemosensitivity and progression is required to fully 
understand these effects.
In summary, these data suggest that IGFBP-2 may 
act as a tumour suppressor in bladder cancer cells as 
it inhibits cell growth, invasion, colony formation and 
reduces markers of EMT. Furthermore, methylation may be 
one mechanism that bladder cancers use to reduce levels 
of IGFBP-2 to promote carcinogenesis. Our work also 
provides preliminary data suggesting that the presence of 
IGFBP-2 in bladder cancer cells may enable them to be 




Recombinant IGFBP-2 was purchased from GroPep 
(Thebarton, S.Australia) and 5-aza-2′-deoxycytidine (5-
AZA) from Sigma-Aldrich (Dorset, UK) . NBI-31772 
was purchased from Tocris (Bristol, UK) and is a small 
non-peptide molecule (molecule weight: 341) which 
was identified almost two decades ago [6]. With no 
biologic activity at the IGF receptors, it interacts with 
IGFBPs by competing specifically against IGF to bind 
all the six IGFBPs non-selectively with high affinity, and 
thus displaces free endogenous IGF-I and IGF-II from 
IGF:IGFBP complexes increasing the free levels of IGF-I 
and/or IGF-II [6]. The freed IGF-I has been shown to be 
bioactive in both in vivo and in vitro studies; therefore, this 
molecule has been used as a nonspecific IGFBP inhibitor 
or IGF-potentiator enhancing IGF signalling. Differences 
in the binding activity of NBI-31772 toward six IGFBPs 
were identified with the highest being to IGFBP-2 and 
IGFBP-4, and the lowest to IGFBP-6 [6].
Cell culture
Human urinary bladder cancer cell lines including 
RT4, T24, UMUC3 and TCCSUP were purchased from 
the American Type Culture Collection (ATCC, Manassas, 
VA). The RT4 cells were cultured in McCoy’s 5A Medium 
(Modified) (Lonza,) and supplemented with 10% foetal 
bovine serum (FBS, Fisher Scientific, Loughborough, 
UK), 1% penicillin and streptomycin (50 IU/ml, Fisher 
Scientific) and 1% L-glutamine solution (200mM, Sigma-
Aldrich). The T24 cells were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Sigma-Aldrich), with 
4500 mg/L glucose and the UMUC3 and TCCSUP were 
cultured in Eagle’s Minimum Essential Medium in Earle’s 
BSS (Fisher Scientific) with non-essential amino acids and 
supplemented as for the RT4 cells.
Cell proliferation and cell death
Cell proliferation was assessed using a trypan blue 
dye exclusion assay as described previously [32, 33].
Transfection of cells with IGFBP-2 siRNA
Cells were transfected with siRNA using HiPerfect 
following the manufacturer’s instructions and as described 
previously [32]. IGFBP-2 was silenced using siRNA (target 
sequence IGFBP-2; CCCGGAGCAGGTTGCAGACAA; 
30 nM for 72 hrs). A non-silencing negative control siRNA 
was used as a control (30 nM for 72 hrs).
Cell Invasion
Cell invasion assays were performed as described 
previously [33]. In brief cells transfected with either non-
silencing or IGFBP-2 siRNA (30 nM for 72 hrs) were 
trypsinized and then seeded into collagen-coated inserts 
at a density of 0.1×106 cells/insert (RT4) and 0.08 × 106 / 
insert (T24 and TCCSUP) and allowed to migrate for 
24 hours. Membranes were then imaged using a Leica 
DMI 6000B microscope in 10 random fields (10× 
magnification). Analysis of the number of invaded cells 
was performed using Image J (NIH). The supernatant 




Extraction of cytoplasmic and nuclear protein 
fractions was achieved using a NE-PER Nuclear and 
Cytoplasmic Extraction Kit (Fisher Scientific). Whole cell 
fractions were obtained by routine whole cell lysis using 
cell lysis buffer. Protein concentrations were determined 
using Pierce BCA Protein Assay (Fisher Scientific) and 
equal amounts of cytosolic, nuclear and whole cell extracts 
were analysed by Western blotting.
Western immunoblotting
Western blot analysis was performed as described 
previously [32, 33]. Briefly, 20 μg of protein were run on 
10% SDS-PAGE , transferred to nitrocellulose membrane 
and immunoblotted with the following antibodies: fibronectin 
(1:500, BD Bioscience, CA, USA), E-cadherin (1:1000, Cell 
Signalling, London, UK), vimentin (1:500, BD Biosciences), 
FASN (1:1000, BD Bioscience), ERα (1:750, Santa Cruz, 
Heidelberg, Germany), cyclin D1 (1:1000, Santa Cruz), 
caveolin-1 (1:500, Santa Cruz), GAPDH (1:5000, Millipore, 
Watford, UK) and tubulin (1:5000, Millipore), following the 
manufacturer's instructions. After incubation with specific 
secondary antibodies conjugated to peroxidise (Sigma-
Aldrich), proteins were visualised by Clarity ECL substrate 
(BioRad, Hertfordshire, UK) using BioRad Chemidoc 
XRS + system and analysed using Image lab software.
Colony formation assay
Colony Formation assays were performed as 
described previously [26]. In brief, cells transfected with 
either non-silencing or IGFBP-2 siRNA (30nM for 72 hrs) 
were trypsinized and then seeded at 10,000 cells/dish. After 
3 weeks, the number and the average size of the colonies 
were counted and calculated using Image J. The supernatant 
was assessed to ensure efficiency of IGFBP-2 knock-down.
Combined bisulfite restriction assay (COBRA)
COBRA was used to investigate the methylation 
status of the IGFBP-2 gene promoter. DNA from untreated 
and treated cells was extracted and bisulfite converted 
with EZ DNA Methylation-DirectKit (ZymoResearch, 
CA, USA) according to the manufacturer's instructions 
and as described previously [27]. The primer pair regions 
in the promoter of IGFBP2 gene were designed using 
MethPrimer tool sequences of primers; IGFBP2 forward, 
5′-GATTGAAAT-TTATTTGAAGGTTAAAA-3′ and 
reverse, 5′-ACTCTAAAAATT-CCCTACTCTTCC-3′ and 
purchased from Thermo Fisher.
Statistical analysis
Data were analysed with SPSS 12.0.1 for Windows 
using one-way ANOVA followed by least significant 
difference (LSD) post-hoc test. A statistically significant 
difference was present at p< 0.05.
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